However, in the TNT trial, no benefit of carboplatin over docetaxel was observed in mTNBC patients with BRCA 1 methylation, BRCA1 mRNA-low tumors, or in patients whose tumor harbored other HRD features, such as a high HRD score (by the Myriad assay) [94]. This evidence concerns the gene BRCA1 and neoplasm.